Amerigen, Ningbo Menovo to develop generic pharmaceuticals in US

LYNDHURST, US/NINGBO, CHINA: Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co Ltd have entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market. Under the terms of the agreement, Amerigen and Menovo will jointly develop products for Amerigen to commercialize in the United States. Menovo will be responsible for manufacturing API and finished product whereas Amerigen will be responsible for clinical, regulatory and commercial activities in the United States. Amerigen will also provide support and assistance to Menovo in obtaining United States Food and Drug Administration (FDA) approval for their finished dose manufacturing site in Daxie, China.

“This collaboration enables each party to leverage its respective strengths and will broaden Amerigen’s product pipeline. Our first product opportunity leverages formulation work already undertaken by Amerigen at its Suzhou facility and Menovo’s leading position with the corresponding API,” said John Lowry, President and CEO, Amerigen.

© Worldofchemicals News